Patents by Inventor Klaus Kirchfield

Klaus Kirchfield has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Lipocalin muteins with binding-affinity for glypican-3 (GPC-3) and use of lipocalin muteins for target-specific delivery to cells expressing GPC-3
    Patent number: 9522940
    Abstract: The present invention relates to novel, specific-binding therapeutic and/or diagnostic lipocalin muteins directed against Glypican-3 (GPC-3). The invention also relates to nucleic acid molecules encoding such muteins and to methods for generation of such muteins and nucleic acid molecules. In addition, the invention also is directed to pharmaceutical compositions comprising such muteins and practical uses of these lipocalin muteins. In addition, the present invention provides methods of using muteins of human lipocalin 2 (Lcn2 or NGAL) for target-specific delivery of therapeutic moieties or detectable labels to cells expressing GPC-3, and related therapeutic and diagnostic utilization.
    Type: Grant
    Filed: May 21, 2013
    Date of Patent: December 20, 2016
    Assignee: Pieris Pharmaceuticals GmbH
    Inventor: Klaus Kirchfield
  • LIPOCALIN MUTEINS WITH BINDING-AFFINITY FOR GLYPICAN-3 (GPC-3) AND USE OF LIPOCALIN MUTEINS FOR TARGET-SPECIFIC DELIVERY TO CELLS EXPRESSING GPC-3
    Publication number: 20150284435
    Abstract: The present invention relates to novel, specific-binding therapeutic and/or diagnostic lipocalin muteins directed against Glypican-3 (GPC-3). The invention also relates to nucleic acid molecules encoding such muteins and to methods for generation of such muteins and nucleic acid molecules. In addition, the invention also is directed to pharmaceutical compositions comprising such muteins and practical uses of these lipocalin muteins. In addition, the present invention provides methods of using muteins of human lipocalin 2 (Lcn2 or NGAL) for target-specific delivery of therapeutic moieties or detectable labels to cells expressing GPC-3, and related therapeutic and diagnostic utilization.
    Type: Application
    Filed: May 21, 2013
    Publication date: October 8, 2015
    Applicant: PIERIS AG
    Inventor: Klaus Kirchfield
  • TEAR LIPOCALIN MUTEINS BINDING IL-4 R ALPHA
    Publication number: 20150283207
    Abstract: The present invention relates to novel muteins derived from human tear lipocalin, which bind to IL 4 receptor alpha. The sequences of the muteins comprise particular combinations of amino acids. In particular a mutated amino acid residue is present at any one or more of the sequence positions 27, 28, 30, 31, 33, 53, 57, 61, 64, 66, 80, 83, 104-106 and 108 of the linear polypeptide sequence of the mature human tear lipocalin. A mutated amino acid residue is also present at any 2 or more of the sequence positions 26, 32, 34, 55, 56, 58 and 63 of the linear polypeptide sequence of the mature human tear lipocalin. The invention also provides a corresponding nucleic acid molecule encoding such a mutein and a method for producing such a mutein and its encoding nucleic acid molecule.
    Type: Application
    Filed: March 23, 2015
    Publication date: October 8, 2015
    Applicant: PIERIS AG
    Inventors: Andreas HOHLBAUM, Alexandra Baehre, Gabriele Matschiner, Stefan Trentmann, Klaus Kirchfield, Hans-Juergen Christian